Morris S F, O'Hanlon D M, McLaughlin R, McHale T, Connolly G E, Given H F
National Breast Cancer Research Institute (NBCRI), University College Hospital, Galway, Ireland.
Eur J Surg Oncol. 2001 Sep;27(6):527-31. doi: 10.1053/ejso.2001.1167.
Expression of the v6 variant isoform of CD44 has been causally associated with the development of metastases. This study, using immunohistochemical techniques, examined the prognostic significance of CD44s and CD44v6 expression.
A cohort of 109 women presenting with stage 2 breast cancer, with a minimum follow-up of 5 years, were assessed.
Eighty percent of patients demonstrated CD44v6 expression on immunohistochemical studies. CD44v6 expression in tissue sections was found to be independent of age, tumour size, grade, and lymph-node status. No significant association was demonstrated between CD44v6 expression and either disease-free or overall survival. Similar findings were observed for CD44s.
CD44s and CD44v6 do not appear to be useful as prognostic indicators in early breast cancer. The increased expression of variant CD44 isoforms seen in breast neoplasia may merely be a marker for loss of control of alternative splicing within tumour tissue.
CD44的v6变异体同种型的表达与转移的发生存在因果关系。本研究采用免疫组织化学技术，检测了CD44s和CD44v6表达的预后意义。
对109例Ⅱ期乳腺癌女性患者进行队列研究，随访时间至少5年。
免疫组织化学研究显示，80%的患者存在CD44v6表达。发现组织切片中的CD44v6表达与年龄、肿瘤大小、分级及淋巴结状态无关。未发现CD44v6表达与无病生存期或总生存期之间存在显著关联。CD44s也有类似的发现。
CD44s和CD44v6似乎并非早期乳腺癌有用的预后指标。在乳腺肿瘤中观察到的变异CD44同种型表达增加可能仅仅是肿瘤组织内可变剪接失控的一个标志物。
